Bausch Health announced the approval by Health Canada of CABTREO Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. CABTREO will be made available through pharmacies across Canada in the fourth quarter this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Paulson buys Everbridge, cuts Anglogold in Q2
- Bausch’s eye-care spinoff plans stuck in standoff with creditors, WSJ reports
- Bausch Health put volume heavy and directionally bearish
- Piper downgrades Bausch Health to Underweight with solvency ‘top of mind’
- Bausch Health downgraded to Underweight from Neutral at Piper Sandler